Non-Core FocusUltragenyx provided an update on the Cyprus2+ study for UX701 in Wilson disease, with the company opting to add a higher dose cohort before moving to Stage 2; this program is not viewed as a core focus for the stock.
Study DelaysThe addition of a higher dose cohort for the UX701 study is expected to delay the study by at least 6 months.
Timeline ExtensionsFor Wilson's disease treatment, additional optimization is needed, which is estimated to push the timeline out by about a year.